CA-DENODO
27.10.2021 09:02:12 CEST | Business Wire | Press release
Denodo , the leader in data virtualization, today announced that its annual global user conference, Denodo DataFest 2021 , which was held in North America (NA), EMEA and APAC, attracted 5,000 worldwide registrants. While DataFest APAC and EMEA were held in a virtual format this year, DataFest NA was conducted in a hybrid mode, attracting hundreds of attendees online and in-person in New York. The attendees, made up of Denodo customers, partners, and subject matter experts, discussed the future of data and analytics involving topics such as logical data fabric, cloud modernization, data mesh, AI/ML and more.
Forrester VP and Principal Analyst Michele Goetz kicked off the conference presenting the Total Economic Impact™ of Data Virtualization using Denodo Platform , while David Loshin, President of Knowledge Integrity at TDWI presented the importance of Logical Data Fabric for Hybrid Cloud. Click here to watch the full conference line up.
“While we are not entirely over the pandemic yet, I was personally touched and thrilled to see the excitement among our customers and partners, both in-person and online who joined us to make this year’s DataFest such a success,” said Ravi Shankar, SVP and CMO at Denodo. “Our customers, partners, and internal subject matter experts presented and discussed topics such as why data lakehouse needs a logical architecture, application of advanced semantics in multi/hybrid cloud scenarios, the need for performance acceleration for advanced analytics and data science, to name a few. It was great to see the strength of our customers’ use cases as the Innovation Award polling saw stiff competition among the finalists.”
Winners and Finalists of Denodo Data Innovation Awards 2021 include:
- North America – Winner Ryan Fattini from City Furniture , for their Digitizing City Furniture’s Business Model use case; finalist Jonathan Paul from Fifth Third Bank , for their Digital Transformation and Regulatory Excellence use case.
- APAC – Winner Shaurya Bhasin from GeTS , for their Logical Data Fabric use case; finalist Wilbertus Darmadi from Toyota Astra Motor , for their Data Catalog based Self-Service use case.
- EMEA – Winner Jan Swanepoel from NedBank , for their Largest Data Warehouse on the Planet use case; finalist, Luis Guadarrama from Engie for their data-driven initiatives with Logical Data Fabric use case.
“Winning this year’s Data Innovation Award for the APAC region was a great validation of the strength of our data virtualization use cases and the results we were able to achieve,” said Shaurya Bhasin, Data Platform Lead at GeTS. “In building our unified data platform we were able to offer secure and well governed data access in a multi-cloud scenario. The Denodo Platform is as an important piece of the architecture and I was happy to share our story with the DataFest audience and perhaps it resonated with the audience!”
While Denodo customers played a pivotal role in sharing their business and technical use cases with the audience, it was the amazing network of Denodo Partners which included Accenture, Advanced Analytic Service, Axians, BDO (SimplicityBI), BITanium, CIO Academy Asia (CIOAA), Cognizant, Cyberionix, Dai Nippon Printing, DAMA, Devfacto, EY, Hitachi Solutions, Indium Software, Insight Technology, iOCO, IQZ Systems, JEMS, Mainline, MDI Novare Technologies, Nippon Systemware, NS Solutions, Nucleus Software, Q Perior, Servian, Sirius, UST, Wipro and Zeal that made an event of this scale possible. Denodo’s technology partner AWS took part in a Fireside chat to discuss the important of Logical Data Fabric for successful cloud migration.
Please tweet: #datavirtualization leader Denodo announce the winners of 4th annal Data Innovation Awards During #DataFest 2021. Audience vote @CityFurniture, @CLGeTS and @Nedbank for the most innovative use cases
About Denodo
Denodo is the leader in data virtualization providing agile, high performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit http://www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005047/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom